Douglas Corley to Biomarkers, Tumor
This is a "connection" page, showing publications Douglas Corley has written about Biomarkers, Tumor.
Connection Strength
1.241
-
Early Screening of African Americans (45-50 Years Old) in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program. Gastroenterology. 2020 11; 159(5):1695-1704.e1.
Score: 0.666
-
Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis. 2021 04 17; 42(3):369-377.
Score: 0.175
-
Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterology. 2020 12; 159(6):2065-2076.e1.
Score: 0.168
-
BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol. 2015 May; 110(5):662-82; quiz 683.
Score: 0.116
-
Cross-cancer evaluation of polygenic risk scores for 16 cancer types in two large cohorts. Nat Commun. 2021 02 12; 12(1):970.
Score: 0.043
-
Clinical Molecular Marker Testing Data Capture to Promote Precision Medicine Research Within the Cancer Research Network. JCO Clin Cancer Inform. 2019 09; 3:1-10.
Score: 0.039
-
Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue. Dig Dis Sci. 2017 03; 62(3):678-688.
Score: 0.033